Citation Impact
Citing Papers
A target selection of somatic hypermutations is regulated similarly between T and B cells upon activation-induced cytidine deaminase expression
2005 StandoutNobel
Assay of locus-specific genetic load implicates rare Toll-like receptor 4 mutations in meningococcal susceptibility
2003 StandoutNobel
miR-15 and miR-16 induce apoptosis by targeting BCL2
2005 Standout
Cancer statistics, 2022
2022 Standout
Cancer statistics, 2023
2023 Standout
Cancer statistics, 2020
2020 Standout
Cancer Statistics, 2021
2021 Standout
AML1, the Target of Multiple Chromosomal Translocations in Human Leukemia, Is Essential for Normal Fetal Liver Hematopoiesis
1996 Standout
Southwestern Internal Medicine Conference: Clinical Use of Hematopoietic Growth Factors
1993
Intensive chemotherapy induction followed by interferon-alpha maintenance in patients with Philadelphia chromosome-positive chronic myelogenous leukemia
1991
CDK inhibitors: positive and negative regulators of G1-phase progression
1999 Standout
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
2013 Standout
The p16INK4a/CDKN2A tumor suppressor and its relatives
1998
Chronic myelogenous leukemia in nonlymphoid blastic phase
1999
Epigenetics in human disease and prospects for epigenetic therapy
2004 StandoutNature
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
2002 Standout
Homozygous disruption of the murine MDR2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease
1993 Standout
2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines
2000
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice
1994 StandoutNature
A Prediction Rule to Identify Low-Risk Patients with Community-Acquired Pneumonia
1997 Standout
Head and neck cancer
2008 Standout
Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
2001 Standout
Acute Lymphoblastic Leukemia
1998
Bcr–Abl variants: biological and clinical aspects
2002
Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia
2002
Regression of Metastatic Renal-Cell Carcinoma after Nonmyeloablative Allogeneic Peripheral-Blood Stem-Cell Transplantation
2000 Standout
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults
2009 Standout
A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma
1996 Standout
Early Phase I/II Trials with Gemtuzumab Ozogamicin (Mylotarg®) in Acute Myeloid Leukemia
2002
Chlorambucil in Indolent Chronic Lymphocytic Leukemia
1998
Senescent Cells, Tumor Suppression, and Organismal Aging: Good Citizens, Bad Neighbors
2005 Standout
Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
2011 Standout
Salvage Therapy for Refractory or Relapsed Acute Lymphocytic Leukemia
2001
p16(MTS-1/CDKN2/INK4a) in Cancer Progression
2001
Philadelphia Chromosome–Positive Acute Myeloid Leukemia
2007
The Biology of Chronic Myeloid Leukemia
1999
Cardiotoxicity of Chemotherapeutic Agents
2000
Infectious and immunosuppressive complications of purine analog therapy.
1995
Topoisomerase I inhibitors: topotecan and irenotecan
1994
Due to low infection rates no routine anti‐infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine‐based first line therapy
2006
Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome
2001 Standout
ACUTE MYELOID LEUKAEMIA IN THE ELDERLY: BIOLOGY AND TREATMENT
1993
Maintenance Treatment with Recombinant Interferon Alfa-2b in Patients with Multiple Myeloma Responding to Conventional Induction Chemotherapy
1990
Complement
2001 Standout
B cell–specific and stimulation-responsive enhancers derepress Aicda by overcoming the effects of silencers
2009 StandoutNobel
Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia
2000 Standout
MicroRNA signatures in human cancers
2006 Standout
Analysis of prognostic factors for the outcome of marrow transplantation or further chemotherapy for patients with acute nonlymphocytic leukemia in first remission.
1989 StandoutNobel
Association of mutations in mannose binding protein gene with childhood infection in consecutive hospital series
1997
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial
2000 Standout
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
2014 Standout
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
2014 Standout
Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results.
1994
Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia
1990
Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials
1999 Standout
Chronic Lymphocytic Leukemia
1995
Peripheral T- cell lymphomas: diagnosis and management
2003
Camptothecins: from bench research to hospital wards.
1994
β-Arrestin2 mediates the initiation and progression of myeloid leukemia
2012 StandoutNobel
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
2008 Standout
A point mutation in the murine Hem1 gene reveals an essential role for Hematopoietic Protein 1 in lymphopoiesis and innate immunity
2008 StandoutNobel
Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia
1993
Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring
1999 StandoutScience
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
2002 StandoutScience
Biallelic Mutations in p16INK4a Confer Resistance to Ras- and Ets-Induced Senescence in Human Diploid Fibroblasts
2002
Nonimmunoglobulin target loci of activation-induced cytidine deaminase (AID) share unique features with immunoglobulin genes
2012 StandoutNobel
Pentostatin, Cyclophosphamide, and Rituximab Is an Active, Well-Tolerated Regimen for Patients With Previously Treated Chronic Lymphocytic Leukemia
2006
ATM, CTLA4, MNDA, andHEM1in High versus Low CD38–Expressing B-Cell Chronic Lymphocytic Leukemia
2007
Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients
1990
Apoptosis in the Pathogenesis and Treatment of Disease
1995 StandoutScience
Activation-induced cytidine deaminase acts as a mutator in BCR-ABL1–transformed acute lymphoblastic leukemia cells
2007
Cancer Cell Cycles
1996 StandoutScience
Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase I-DNA cleavage sites.
1995 StandoutNobel
National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment
1996 Standout
Toward the potential cure of leukemias in the next decade
2018
Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia
2003
Evaluation of intensive postremission chemotherapy for adults with acute nonlymphocytic leukemia using high-dose cytosine arabinoside with L-asparaginase and amsacrine with etoposide.
1987 StandoutNobel
p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression
1993
Drug Delivery Systems: Entering the Mainstream
2004 StandoutScience
An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology.
1999
Chimeric Antigen Receptor Therapy
2018 Standout
Fluorescent in situ hybridization and cytogenetic studies of trisomy 12 in chronic lymphocytic leukemia
1993
A randomized study of the efficacy of consolidation therapy in adult acute nonlymphocytic leukemia
1984
Cell cycle deregulation in B-cell lymphomas
2003
Treatment of the Newly Diagnosed Adult with De Noyo Acute Myeloid Leukemia
1993
Hematopoietic growth factors and their receptors in acute leukemia
1993
The biology and treatment of acute lymphoblastic leukemia in adults
1995
Molecular pathogenesis of the chromosome 16 inversion in the M4Eo subtype of acute myeloid leukemia [see comments]
1995
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies
2003
p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias
1995
Clonotypic polymerase chain reaction confirms minimal residual disease in CLL nodular PR: results from a sequential treatment CLL protocol
2001
Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics
1999 StandoutScience
Multiple event activation of a generic prodrug trigger by antibody catalysis
1999 StandoutNobel
High expression of the mdr3 multidrug-resistance gene in advanced-stage chronic lymphocytic leukemia
1992
Phylogenetic Perspectives in Innate Immunity
1999 StandoutScienceNobel
Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment [see comments]
1993
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
2016 Standout
Cyclin E overexpression in relapsed adult acute lymphoblastic leukemias of B-cell lineage
1996
Treatment of the newly diagnosed adult with de novo acute myeloid leukemia.
1993
Chronic Myelogenous Leukemia: Biology and Therapy
1999
Works of MJ Keating being referenced
Prognosis of chronic lymphocytic leukemia: a multivariate regression analysis of 325 untreated patients
1987
Significance of the levels of bone marrow lymphoid infiltrate in chronic lymphocytic leukemia patients with nodular partial remission
2002
Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL)
2002
Treatment of patients over 50 years of age with acute myelogenous leukemia with a combination of rubidazone and cytosine arabinoside, vincristine, and prednisone (ROAP)
1981
2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders
1994
Intensive chemotherapy with mitoxantrone and high-dose cytosine arabinoside followed by granulocyte-macrophage colony-stimulating factor in the treatment of patients with acute lymphocytic leukemia
1992
Fludarabine: a new agent with major activity against chronic lymphocytic leukemia
1989
A unique pattern of central nervous system leukemia in acute myelomonocytic leukemia associated with inv(16)(p13q22)
1985
Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis [see comments]
1992
Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia
1991
Intensive chemotherapy with mitoxantrone and high-dose cytosine arabinoside followed by granulocyte-macrophage colony-stimulating factor in the treatment of patients with acute lymphocytic leukemia
1992
Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA)
1992
Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia
1993
Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions
1996
Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia
1991
Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA)
1992
Causes of initial remission induction failure in acute myelogenous leukemia
1982
Treatment of poor-prognosis, newly diagnosed acute myeloid leukemia with ara-C and recombinant human granulocyte-macrophage colony- stimulating factor
1990
The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia
1995
Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent
1993
Fludarabine therapy in macroglobulinemic lymphoma
1990
Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent
1993
p16INK4A and p15INK4B gene deletions in primary leukemias
1995
Causes of initial remission induction failure in acute myelogenous leukemia
1982
Clinical investigation of human alpha interferon in chronic myelogenous leukemia
1987
Fludarabine and granulocyte colony-stimulating factor (G-CSF) in patients with chronic lymphocytic leukemia
1997
Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia
1993
Evaluation of AMSA in previously treated patients with acute leukemia: results of therapy in 109 adults
1982